Aditxt, Inc. Other Selling and Marketing Expense
Aditxt, Inc. (ADTX) reported Other Selling and Marketing Expense of $5.04 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherSellingAndMarketingExpense · last filed 2023-08-14
- Aditxt, Inc. other selling and marketing expense for the quarter ending 2023-06-30 was $2.53K.
- Aditxt, Inc. other selling and marketing expense for the quarter ending 2023-03-31 was $2.50K.
- Aditxt, Inc. other selling and marketing expense for the quarter ending 2022-09-30 was $0.00.
| Period end | Other Selling and Marketing Expense 3 month | Other Selling and Marketing Expense 6 month | Other Selling and Marketing Expense 9 month |
|---|---|---|---|
| 2023-06-30 | $2.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $5.04K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $2.50K 10-Q · filed 2023-05-15 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $504.70K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $504.70K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |